NDA 021330 · Haleon US Holdings
Nicorette
Nicotine Polacrilex · Oral · Cholinergic Nicotinic Agonist
Last checked: Nov 20, 2026Latest source record: Sep 6, 2024 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2002
Oct 31, 2002
Approved uses
2
Original approval plus efficacy supplements
Registered trials
873
97 Phase 3, 66 recruiting
FAERS reports
19,235
3,825 serious, 148 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect Jun 4, 2025.
Use reduces withdrawal symptoms, including nicotine craving, associated with quitting smoking
Therapeutic areas: Rare and genetic disease
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- May 23, 2012 Supplement 13 · Efficacy ReviewLetter
- Oct 31, 2002 Original approval · Type 3 - New Dosage Form LetterReview
2 products under this application
- NICORETTE · NICOTINE POLACRILEX EQ 2MG BASE · TROCHE/LOZENGE, ORAL · Over-the-counter
- NICORETTE · NICOTINE POLACRILEX EQ 4MG BASE · TROCHE/LOZENGE, ORAL · Over-the-counter
Clinical trials
Interventional ClinicalTrials.gov studies with "Nicotine Polacrilex" as an intervention, any sponsor and status, largest first.
- BREATHE 2 Clinic Stop-Smoking Treatment Outreach StudyPivotal-lookingCompleted
University of Wisconsin, MadisonAcademic, hospital or other
NCT05683821 · 12,376 participants · Start Jul 24, 2023 · Primary completion May 7, 2025
Drug: Nicotine replacement therapy sampling · For: Quitting Smoking; Smoking Cessation; Smoking, Cigarette
Sites: Madison, Wisconsin
- Study Evaluating The Safety And Efficacy Of Varenicline and Bupropion For Smoking Cessation In Subjects With And Without A History Of Psychiatric DisordersPivotal-lookingCompleted
PfizerPfizer (PFE)
NCT01456936 · 8,144 participants · Start Nov 2011 · Primary completion Jan 2015
Drug: Placebo; varenicline tartrate and 2 more · For: Smoking Cessation
Sites: Mobile, Alabama; Phoenix, Arizona; Encino, California · 156 sites in all
Centre for Addiction and Mental HealthAcademic, hospital or other
NCT00356993 · 6,009 participants · Start Oct 2005 · Primary completion Mar 30, 2018
Drug: Nicotine Replacement Therapy · For: Smoking
Sites: Toronto, Canada
- Study To Evaluate Cardiac Assessments Following Different Treatments Of Smoking Cessation Medications In Subjects With And Without Psychiatric Disorders.Pivotal-lookingCompleted
PfizerPfizer (PFE)
NCT01574703 · 4,595 participants · Start May 2012 · Primary completion Jul 2015
Drug: placebo; varenicline tartrate and 2 more · For: Smoking Cessation
Sites: Mobile, Alabama; Encino, California; Escondido, California · 134 sites in all
- Telephone Counseling and the Distribution of Nicotine Patches to SmokersPivotal-lookingCompleted
University of California, San DiegoAcademic, hospital or other
NCT00851357 · 4,200 participants · Start Feb 2009 · Primary completion Oct 2010
Drug: Nicotine Patch; Placebo · For: Smoking Cessation
Sites: San Diego, California
- A Randomized Trial of Medi-Cal Beneficiaries Calling the California Smokers' HelplinePivotal-lookingCompleted
University of California, San DiegoAcademic, hospital or other
NCT01502306 · 3,816 participants · Start Jun 2012 · Primary completion Feb 2014
Drug: Nicotine patches · For: Smoking Cessation
Sites: San Diego, California
- Providing Free Nicotine Patches to Quitline SmokersPivotal-lookingCompleted
University of California, San DiegoAcademic, hospital or other
NCT01736085 · 3,706 participants · Start Apr 2013 · Primary completion Nov 2014
Drug: Nicotine patches · For: Smoking Cessation
Sites: San Diego, California
- ISTAPS: A Stepped Primary Care Smoking Cessation InterventionPivotal-lookingStatus unknown
Fundacio d'Investigacio en Atencio Primaria Jordi Gol i GurinaAcademic, hospital or other
NCT00125905 · 3,012 participants · Start Oct 2003
Drug: Nicotine Gum and Patch; Bupropion · For: Smoking Cessation
Sites: Barcelona, Spain
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- drug ineffective3,352
- nicotine dependence3,000
- intentional drug misuse2,815
- nausea1,648
- drug administration error1,007
- malaise856
- oral discomfort630
- wrong technique in product usage process620
- dizziness590
- dyspepsia573
- macular degeneration568
- headache550
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2004 | 113 |
| 2005 | 188 |
| 2006 | 726 |
| 2007 | 1,058 |
| 2008 | 881 |
| 2009 | 940 |
| 2010 | 947 |
| 2011 | 1,180 |
| 2012 | 1,319 |
| 2013 | 1,064 |
| 2014 | 218 |
| 2015 | 1,302 |
| 2016 | 1,236 |
| 2017 | 1,252 |
| 2018 | 1,068 |
| 2019 | 942 |
| 2020 | 883 |
| 2021 | 1,028 |
| 2022 | 776 |
| 2023 | 656 |
| 2024 | 508 |
| 2025 | 609 |
| 2026 | 341 |
Recalls
2 FDA enforcement reports for this application.
Feb 20, 2014 · Class III · Terminated
Failed Lozenge Specifications; Lozenges are overly thick, overly soft, and sub and superpotent.
Feb 20, 2014 · Class III · Terminated
Failed Lozenge Specifications; Lozenges are overly thick, overly soft, and sub and superpotent.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Nicorette--an update.
· Drug Ther Bull 1985 · Clinical Trial
- Controlled trial of nicotine polacrilex gum with supportive measures.
Blöndal T · Arch Intern Med 1989 · Clinical Trial, Controlled Clinical Trial
- Effects of behavioral and pharmacological treatment on smokeless tobacco users.
Hatsukami D, Jensen J, Allen S, et al. · J Consult Clin Psychol 1996 · Clinical Trial, Comparative Study
- Gingival response to nicotine polacrilex.
Silver KJ, Sachs DP, Hottel TL · J Am Dent Assoc 1989 · Clinical Trial, Multicenter Study
- Influence of nicotine on simulator flight performance in non-smokers.
Mumenthaler MS, Taylor JL, O'Hara R, et al. · Psychopharmacology (Berl) 1998 · Clinical Trial, Research Support, Non-U.S. Gov't
- The effect of nicotine on visuospatial attention in chronic spatial neglect depends upon lesion location.
Vossel S, Kukolja J, Thimm M, et al. · J Psychopharmacol 2010 · Randomized Controlled Trial, Research Support, Non-U.S. Gov't
Sponsor: Haleon US Holdings
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.